Cixutumumab

{
  "id": "MLC-T-ONC-001792",
  "term": "Cixutumumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of some types of cancer. It is a monoclonal antibody that is made in the laboratory and can bind to substances in the body. Cixutumumab blocks the action of a protein needed for cell growth and may kill cancer cells. It is a type of insulin-like growth factor-1 receptor (IGF-1R) inhibitor. Also called IMC-A12.",
    "A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis."
  ],
  "synonyms": [
    "IMC-A12",
    "anti-IGF-1R recombinant monoclonal antibody IMC-A12"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cixutumumab/"
}